A minimally Invasive surgical platform aGainst paNcreatIc and biliary Tract cancErs using cold atmospheric PLASMA

癌症是欧洲人死亡的主要原因之一。胰腺（PC）和胆道（BTC）癌是一种罕见的胃肠道腺癌，在欧洲老龄化人口中发病率越来越高，特别是在老年人和妇女中，预后不良构成了重大的临床挑战和公共卫生负担。冷大气压等离子体（CAP）在实验室环境中显示出对多种癌症类型的潜在消退。由于它们的性质，CAP是高浓度活性自由基、电子、离子、紫外线等的独特来源，可在活组织中诱导各种效应。CAP在治疗癌细胞的地方显示出选择性，对健康细胞的影响最小；这使得血浆适合于治疗非常敏感的区域或器官的癌症，这些区域或器官存在未满足的最小化损害/副作用的需求。CAP可以通过可变长度的介电管输送，这使得它非常适合微创和精确的腹腔镜和内窥镜手术。尽管这一概念具有巨大的前景和潜力，但目前市场上还没有基于CAP的单一腹腔镜或内窥镜医疗平台来治疗癌症。该项目提出了一种新颖的解决方案，使用尖端的等离子体技术、硅模型和系统级方法。它将结合血浆和肿瘤多尺度模拟，并将从手术前诊断中获取输入，用于计算机模型初始化和CAP操作窗口确定。该项目将通过体内实验验证所开发的技术，为PC/ btc基于cap的护理的临床试验和市场引入奠定基础。

Cancer is one of the major causes of death in Europe. Pancreatic (PC) and biliary tract (BTC) cancer are rare gastrointestinal adenocarcinomas with an increasing incidence particularly among the elderly and women in an ageing European population, and a poor prognosis poses major clinical challenges and public health burden. Cold atmospheric pressure plasma (CAP) has shown potential regressing various cancer types in the laboratory setting. Owing to their properties, CAP is a unique source of high concentrations of reactive radicals, electrons, ions, UV etc. that may induce various effects in living tissue. CAP has shown selectivity in where cancer cells are treated with minimal effect to healthy ones; this renders plasma suitable to treat carcinomas in very sensitive areas or organs where an unmet need to minimise damage/side-effects exists. CAP can be delivered through dielectric tubes of variable length, which makes it ideal for minimally invasive and precise laparoscopic and endoscopic operations. Despite the great promise and potential of this concept, there is no single laparoscopic or endoscopic medical platform in the market today based on CAP to treat carcinomas. This project proposes a novel solution using cutting-edge plasma technology, in-silico models, and a system-level approach. It will combine plasma with tumour multiscale simulations and will take input from pre-surgery diagnostics for in-silico model initialisation and CAP operational window determination. The developed technology will be demonstrated through in-vivo experiments, while the foundations for clinical trials and market introduction for CAP-based care of PC/BTCs will be laid out in this project.